Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2024 10:10 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public...
February 29, 2024 21:14 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of...
February 28, 2024 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

HAMPTON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market...
February 26, 2024 07:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

- Phase 3 CSU studies expected to initiate in summer 2024 -- Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 --...
February 24, 2024 14:05 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups -- Sustained activity with rapid...
February 06, 2024 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

HAMPTON, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th...
February 05, 2024 08:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024

HAMPTON, N.J., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing 12 week results from the Company’s Phase 2 clinical trial of...
November 27, 2023 16:15 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference

HAMPTON, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the 6th Annual Evercore ISI...
November 07, 2023 23:15 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics Announces Pricing of Public Offering of Common Stock

HAMPTON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 7,425,000...
November 07, 2023 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

HAMPTON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market...